NMR spectroscopic analyses of liver phosphatidylcholine and phosphatidylethanolamine biosynthesis in rats exposed to peroxisome proliferators - A class of nongenotoxic hepatocarcinogens

Toxicology and Applied Pharmacology

Volumn 164, Issue 2, 2000, Pages 113-126

  Reo, Nicholas V ^a,b   Adinehzadeh, Mehdi ^a,c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c KETTERING MEDICAL CENTER   (United States)

Author keywords

Liver phospholipids; NMR spectroscopy; Peroxisome proliferators; Phosphatidylcholine; Phosphatidylethanolamine

Indexed keywords

CARBON 13; CARCINOGEN; CHOLINE; ETHANOLAMINE; PERFLUORODECANOIC ACID; PERFLUOROOCTANOIC ACID; PEROXISOME PROLIFERATOR; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PIRINIXIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; ISOTOPE LABELING; LIVER CANCER; LIVER CARCINOGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID SYNTHESIS; RAT;

ANIMALIA; RODENTIA;

EID: 0034655357     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.2000.8901     Document Type: Article

References (75)

1. Abdellatif A. G., Preat V., Taper H. S., Roberdfroid M. The modulation of rat liver carcinogenesis by perfluorooctanoic acid, a peroxisome proliferator. Toxicol. Appl. Pharmacol. 111:1991;530-537.
2. Abdellatif A. G., Vamecq J., Nilsson R., Roberfroid M. Peroxisome proliferation and modulation of rat liver carcinogenesis by 2,4-dichlorophenoxyacetic acid, 2,4,5-trichlorophenoxyacetic acid, perfluorooctanoic acid and nafenopin. Carcinogenesis. 11:1990;1899-1902.
3. 31P chemical shifts and absolute quantitation. Q. Magn. Reson. Biol. Med. 3:1996;171-176.
4. Adinehzadeh M., Reo N. V. Effects of peroxisome proliferators on rat liver phospholipids: Sphingomyelin degradation may be involved in hepatotoxic mechanism of perfluorodecanoic acid. Chem. Res. Toxicol. 11:1998;428-440.
5. Adinehzadeh M., Reo N. V., Jarnot B. M., Taylor C. A., Mattie D. R. Dose-response hepatotoxicity of the peroxisome proliferator, perfluorodecanoic acid, and the relationship to phospholipid metabolism in rats. Toxicology. 134:1999;179-195.
6. Bojes H. K., Thurman R. G. Peroxisome proliferators inhibit acyl CoA synthetase and stimulate protein kinase C in vivo. Toxicol. Appl. Pharmacol. 126:1994;233-239.
7. Borges T., Peterson R. E., Pitot H. C., Robertson L. W., Glauert H. P. Effect of the peroxisome proliferator, perfluorodecanoic acid, on the promotion of two-state hepatocarcinogenesis in rats. Cancer Lett. 72:1993;111-120.
8. Borges T., Robertson L. W., Peterson R. E., Glauert H. P. Dose-related effects of perfluorodecanoic acid in growth, feed intake and hepatic peroxisomal β-oxidation. Arch. Toxicol. 66:1992;18-22.
9. Cui Z., Houweling M., Vance D. E. Suppression of rat hepatoma cell growth by expression of phosphatidylethanolamine N-methyltransferase-2. J. Biol. Chem. 269:1994;24531-24533.
10. Cui Z., Shen Y. J., Vance D. E. Inverse correlation between expression of phosphatidylethanolamine N-methyltransferase-2 and growth rate of perinatal rat livers. Biochim. Biophys. Acta. 1346:1997;10-16.
11. Cui Z., Vance J. E., Ming H. C., Voelker D. R., Vance D. E. Cloning and expression of a novel phosphatidylethanolamine N-methyltransferase: A rat specific biochemical and cytological marker for a unique membrane fraction in rat liver. J. Biol. Chem. 268:1993;16655-16663.
12. Das A. K., Horie S., Hajra A. K. Biosynthesis of glycerolipid precursors in rat liver peroxisomes and their transport and conversion to phosphatidate in the endoplasmic reticulum. J. Biol. Chem. 267:1992;9724-9730.
13. DeLong C. J., Shen Y. J., Thomas M. J., Cui Z. Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway [in process citation]. J. Biol. Chem. 274:1999;29683-29688.
14. George M. E., Andersen M. E. Toxic effects of nonadecafluoro-n-decanoic acid in rats. Toxicol. Appl. Pharmacol. 85:1986;169-180.
15. Gibson G. G. Peroxisome proliferation: Mechanisms and biological consequences. Biochem. Soc. Trans. 18:1990;85-99.
16. Gibson G. G. Peroxisome proliferators: Paradigms and prospects. Toxicol. Lett. 68:1993;193-201.
17. Goecke C. M., Jarnot B. M., Reo N. V. A comparative toxicological investigation of perfluorocarboxylic acids in rats by fluorine-19 NMR spectroscopy. Chem. Res. Toxicol. 5:1992;512-519.
18. 13C NMR investigation. Chem. Res. Toxicol. 7:1994;15-22.
19. 31P investigation. Chem. Res. Toxicol. 9:1996;689-695.
20. Goecke-Flora C. M., Wyman J. F., Jarnot B. M., Reo N. V. Effects of the peroxisome proliferator perfluoro-n-decanoic acid on glucose transport in the isolated perfused rat liver. Chem. Res. Toxicol. 8:1995;77-81.
21. Gonzalez F. J. The role of peroxisome proliferator activated receptor α in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv. Exp. Med. Biol. 422:1997;109-125.
22. Gore S. D., Samid D., Weng L. J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res. 3:1997;1755-1762.
23. Green S. Commentary: Receptor-mediated mechanisms of peroxisome proliferators. Biochem. Pharmacol. 43:1992;393-401.
24. Green S. PPAR: A mediator of peroxisome proliferator action. Mutat. Res. 333:1995;101-109.
25. Hatch G., Vance D. Stimulation of sphingomyelin biosynthesis by brefeldin A and sphingomyelin breakdown by okadaic acid treatment of rat hepatocytes. J. Biol. Chem. 267:1992;12443-12451.
26. Hawkins J. M., Jones W. E., Bonner F. W., Gibson G. G. The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metab. Rev. 18:1987;441-515.
27. Houweling M., Cui Z., Tessitore L., Vance D. E. Induction of hepatocyte proliferation after partial hepatectomy is accompanied by a markedly reduced expression of phosphatidylethanolamine N-methyltransferase-2. Biochim. Biophys. Acta. 1346:1997;1-9.
28. Houweling M. Phosphatidylcholine metabolism in rat liver after partial hepatectomy. Biochem. J. 278:1991;347-351.
29. Kawashima Y., Hirose A., Kozuka H. Alterations by peroxisome proliferators of acyl composition of hepatic phosphatidylcholine in rats, mice and guinea pigs. Biochem. J. 235:1986;251-255.
30. Kawashima Y. Co-induction of peroxisome proliferators of microsomal 1-acylglycerophosphocholine acyltransferase with peroxisomal β-oxidation in rat liver. Biochim. Biophys. Acta. 1005:1989;123-129.
31. Kawashima Y., Mizuguchi H., Musoh K., Kozuka H. The mechanism of increased supply of phosphatidylcholine for the proliferation of biological membranes by clofibric acid, a peroxisome proliferator. Biochim. Biophys. Acta. 1212:1994;311-318.
32. Kent C. Regulation of phosphatidylcholine biosynthesis. Prog. Lipid Res. 29:1990;87-105.
33. Kent C. Eukaryotic phospholipid biosynthesis. Annu. Rev. Biochem. 64:1995;315-343.
34. 1 mice. J. Toxicol. Environ. Health. 10:1982;797-815.
35. 31P NMR studies of cultured human tumor cells: Influence of pH on phospholipid metabolite levels and the detection of cytidine 5′-diphosphate choline. NMR Biomed. 3:1990;78-89.
36. Lake B. G. Mechanisms of hepatocarcinogenicity of peroxisome proliferating drugs and chemicals. Annu. Rev. Pharmacol. Toxicol. 35:1995;483-507.
37. Lalwani N., Reddy K., Qureshi S. A., Reddy J. K. Development of hepatocellular carcinomas and increased peroxisome fatty acid β-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet. Carcinogenesis. 2:1981;645-650.
38. Mannaerts G. P., Van Veldhoven P. P. Metabolic role of mammalian peroxisomes. Gibson G., Lake B. Peroxisomes: Biology and Importance in Toxicology and Medicine. 1993;19-62 Taylor & Francis, Washington.
39. Marsman D. S., Popp J. A. Importance of basophilic hepatocellular foci in the development of hepatic tumors induced by the peroxisome proliferator, Wy-14,643. Proc. Am. Assoc. Cancer Res. 30:1989;193.
40. 31P NMR of extracted phospholipids. J. Lipid Res. 29:1988;679.
41. Milton M. N., Elcombe C. R., Gibson G. G. On the mechanism of induction of microsomal cytochrome P450IVA1 and peroxisome proliferation in rat liver by clofibrate. Biochem. Pharmacol. 40:1990;2727-2732.
42. Nishimaki-Mogami T., Suzuki K., Okochi E., Takahashi A. Bezafibrate and clofibric acid are novel inhibitors of phosphatidylcholine synthesis via the methylation of phosphatidylethanolamine. Biochim. Biophys. Acta. 1304:1996a;11-20.
43. Nishimaki-Mogami T., Suzuki K., Takahashi A. The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: Rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteins. Biochim. Biophys. Acta. 1304:1996b;21-31.
44. Carcinogenesis Bioassay of Di(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 Rats and B6C3F1 Mice. 1983.
45. Olson C. T., Andersen M. E. The acute toxicity of perfluorooctanoic and perfluorodecanoic acids in male rats and effects on tissue fatty acids. Toxicol. Appl. Pharmacol. 70:1983;362-372.
46. Parthasarathy S., Kritchevsky D., Baumann W. J. Hypolipidemic drugs are inhibitors of phosphatidylcholine synthesis. Proc. Natl. Acad. Sci. USA. 79:1982;6890-6893.
47. Pelech S. L., Vance D. E. Regulation of phosphatidylcholine biosynthesis. Biochim. Biophys. Acta. 779:1984;217-251.
48. Prasanna P., Shack S., Wilson V. L., Samid D. Phenylacetate in chemoprevention: In vitro and in vivo suppression of 5-aza-2′-deoxycytidine-induced carcinogenesis. Clin. Cancer Res. 1:1995;865-871.
49. Rao M., Lawani N., Reddy J. Sequential histologic study of rat liver during peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]aceticacid (Wy-14,643)-induced carcinogenesis. J. Natl. Cancer Inst. 73:1984;983-990.
50. Rao M. S., Reddy J. K. An overview of peroxisome proliferator-induced hepatocarcinogenesis. Environ. Health Perspect. 93:1991;205-209.
51. Reddy J. K., Krishnakantha T. P. Hepatic peroxisome proliferation: Induction by two novel compounds structurally unrelated to clofibrate. Science. 190:1975;787-789.
52. Reddy J. K., Rao M. S., Azarnoff D. L., Sell S. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rat and mouse liver. Cancer Res. 39:1979;152-161.
53. Reo N. V., Goecke C. M., Narayanan L., Jarnot B. M. Effects of perfluoro-n-octanoic acid, perfluoro-n-decanoic acid, and clofibrate on hepatic phosphorus metabolism in rats and guinea pigs in vivo. Toxicol. Appl. Pharmacol. 124:1994;165-173.
54. Reo N. V., Narayanan L., Kling K. B., Adinehzadeh M. Perfluorodecanoic acid, a peroxisome proliferator, activates phospholipase C, inhibits CTP:phosphocholine cytidylyltransferase, and elevates diacylglycerol in rat liver. Toxicol. Lett. 86:1996;1-11.
55. Ruiz-Cabello J., Cohen J. S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 5:1992;226-233.
56. Samid D. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med. Biol. 400A:1997;501-505.
57. Samid D., Shack S., Myers C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91:1993;2288-2295.
58. Sausen P. J., Lee D. C., Rose M. L., Cattley R. C. Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: Relationship to mitochondrial alterations. Carcinogenesis. 16:1995;1795-1801.
59. Sharma R., Lake B. G., Gibson G. G. Co-induction of microsomal cytochrome P-452 and the peroxisomal fatty acid β-oxidation pathway in the rat by clofibrate and di-(2-ethylhexyl)phthalate. Biochem. Pharmacol. 37:1988;1203-1206.
60. Sonsoles L. L., Stetler-Stevenson W. G., Hudgins W. R., Samid D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Invest. Dermatol. 103:1994;335-340.
61. Tessitore L., Cui Z., Vance D. E. Transient inactivation of phosphatidylethanolamine N-methyltransferase-2 and activation of cytidine triphosphate:phosphocholine cytidylyltransferase during non-neoplastic liver growth. Biochem. J. 322:1997;151-154.
62. Tessitore L., Dianzani I., Cui Z., Vance D. E. Diminished expression of phosphatidylethanolamine N-methyltransferase 2 during hepatocarcinogenesis. Biochem. J. 337:1999a;23-27.
63. Tessitore L., Sesca E., Bosco M., Vance D. E. Expression of phosphatidylethanolamine N-methyltransferase in Yoshida ascites hepatoma cells and the livers of host rats. Carcinogenesis. 20:1999b;561-567.
64. Thorne P. C., Byers D. M., Palmer F. B., Cook H. W. Clofibrate and other peroxisomal proliferating agents relatively specifically inhibit synthesis of ethanolamine phosphoglycerides in cultured human fibroblasts. Biochim. Biophys. Acta. 1214:1994;161-170.
65. Tyagi R. K., Azard A., Degani H., Salomon Y. Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn. Reson. Med. 35:1996;194-200.
66. Vance D. E. Phosphatidylethanolamine N-methyltransferase: Unexpected findings from curiosity-driven research. Eur. J. Med. Res. 1:1996;182-188.
67. Vance D. E., Houweling M., Lee M., Cui Z. Phosphatidylethanolamine methylation and hepatoma cell growth. Anticancer Res. 16:1996;1413-1416.
68. Vance D. E., Walkey C. J. Roles for the methylation of phosphatidylethanolamine. Curr. Opin. Lipidol. 9:1998;125-130.
69. Vanden Heuvel J. P. Perfluorodecanoic acid as a useful pharmacologic tool for study of peroxisome proliferation. Gen. Pharmacol. 27:1996;1123-1129.
70. Vanden Heuvel J. P., Kuslikis B. I., Van Rafelghem M. J., Peterson R. E. Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats. J. Biochem. Toxicol. 6:1991;83-92.
71. Vazquez M. Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. Br. J. Pharmacol. 116:1995;2067-2075.
72. Wada N., Marsman D. S., Popp J. A. Dose-related effects of the hepatocarcinogen, Wy-14,643, on peroxisomes and cell replication. Fundam. Appl. Toxicol. 18:1992;149-154.
73. Witzmann F. A., Jarnot B. M., Parker D. N., Clack J. W. Modification of hepatic immunoglobulin heavy chain binding protein (BiP/Grp78) following exposure to structurally diverse peroxisome proliferators. Fundam. Appl. Toxicol. 23:1994;1-8.
74. Witzmann F. A., Parker D. N. Hepatic protein pattern alterations following perfluorodecanoic acid exposure in rats. Toxicol. Lett. 57:1991;29-36.
75. Yanagita T., Satoh M., Enomoto N., Sugano M. Di(2-ethylhexyl)phthalate enhance hepatic phospholipid synthesis in rats. Biochim. Biophys. Acta. 919:1987;64-70.